{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:37:26Z","timestamp":1700584646986},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2161,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1111\/j.1365-2230.2009.03320.x","type":"journal-article","created":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T10:02:23Z","timestamp":1243850543000},"page":"e368-e369","source":"Crossref","is-referenced-by-count":5,"title":["Erythema multiforme induced by sorafenib"],"prefix":"10.1093","volume":"34","author":[{"given":"R. A.","family":"Feltes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Feito Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Gonz\u00e1lez-Beato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2230.2009.03320.x-BIB1","unstructured":"1Bayer Pharmaceuticals, West Haven, CT. Nexavar (sorafenib) tablets oral: product information. Available at: http:\/\/www.univgraph.com\/bayer\/inserts\/NexavarNAV_PI.pdf. accessed 12 November 2008."},{"key":"10.1111\/j.1365-2230.2009.03320.x-BIB2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003495-200767030-00009","article-title":"Sorafenib: in advanced renal cancer","volume":"67","author":"McKeage","year":"2007","journal-title":"Drugs"},{"key":"10.1111\/j.1365-2230.2009.03320.x-BIB3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2230.2009.03320.x-BIB4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejca.2005.11.014","article-title":"Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumor: Is rash associated with treatment outcome?","volume":"42","author":"Strumberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1365-2230.2009.03320.x-BIB5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2006.10.981","article-title":"Sorafenib-induced erythema multiforme","volume":"56","author":"MacGregor","year":"2006","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2230.2009.03320.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2230.2009.03320.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:29:13Z","timestamp":1676384953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/34\/7\/e368\/6625149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":5,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03320.x","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}